The development of live attenuated cold-adapted influenza virus vaccine for humans.
Identifieur interne : 002E48 ( Main/Exploration ); précédent : 002E47; suivant : 002E49The development of live attenuated cold-adapted influenza virus vaccine for humans.
Auteurs : H F Maassab [États-Unis] ; M L BryantSource :
- Reviews in medical virology [ 1052-9276 ]
Descripteurs français
- KwdFr :
- Adaptation physiologique, Basse température, Grippe humaine (), Humains, Vaccins antigrippaux (immunologie), Vaccins atténués (immunologie), Virus de la grippe A (croissance et développement), Virus de la grippe A (génétique), Virus de la grippe A (immunologie), Virus influenza B (croissance et développement), Virus influenza B (génétique), Virus influenza B (immunologie).
- MESH :
- croissance et développement : Virus de la grippe A, Virus influenza B.
- génétique : Virus de la grippe A, Virus influenza B.
- immunologie : Vaccins antigrippaux, Vaccins atténués, Virus de la grippe A, Virus influenza B.
- Adaptation physiologique, Basse température, Grippe humaine, Humains.
English descriptors
- KwdEn :
- Adaptation, Physiological, Cold Temperature, Humans, Influenza A virus (genetics), Influenza A virus (growth & development), Influenza A virus (immunology), Influenza B virus (genetics), Influenza B virus (growth & development), Influenza B virus (immunology), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Vaccines, Attenuated (immunology).
- MESH :
- chemical , immunology : Influenza Vaccines, Vaccines, Attenuated.
- genetics : Influenza A virus, Influenza B virus.
- growth & development : Influenza A virus, Influenza B virus.
- immunology : Influenza A virus, Influenza B virus.
- prevention & control : Influenza, Human.
- Adaptation, Physiological, Cold Temperature, Humans.
Abstract
A procedure to attenuate live influenza virus of type A and type B was developed using adaptation of the virus to grow at 25 degrees C (cold adaptation; ca). Through a series of stepwise passages, two stable mutants were obtained and designated as 'Master' strains, one for type A influenza virus (A/Ann Arbor/6/60-H2N2) and one for type B influenza virus (B/Ann Arbor/1/66). These mutants were used in genetic reassortment using either the classical method or more recently described reverse genetics to update the relevant surface antigens of the circulating strains of influenza virus. The derivation is based on the concept of 6/2 where 6 signifies the six internal genes of the master strain and 2 refers to the two genes coding for the two surface glycoproteins HA and NA of the circulating influenza virus. The advantages of this vaccine were demonstrated to be (1) proper level of attenuation, (2) non-transmissibility, (3) genetic stability, (4) presence of the ca and ts markers and (5) immunogenicity involving both local and the cell-mediated immune responses. The clinical trials in infants, children, adults and elderly have provided the necessary data for eventual licensing of this vaccine. The ease of administration (intranasal) safety and high efficacy make this vaccine suitable to prevent influenza virus infection in all age groups.
DOI: 10.1002/(sici)1099-1654(199910/12)9:4<237::aid-rmv252>3.0.co;2-g
PubMed: 10578119
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000373
- to stream PubMed, to step Curation: 000373
- to stream PubMed, to step Checkpoint: 000612
- to stream Ncbi, to step Merge: 000011
- to stream Ncbi, to step Curation: 000011
- to stream Ncbi, to step Checkpoint: 000011
- to stream Main, to step Merge: 003023
- to stream Main, to step Curation: 002E48
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The development of live attenuated cold-adapted influenza virus vaccine for humans.</title><author><name sortKey="Maassab, H F" sort="Maassab, H F" uniqKey="Maassab H" first="H F" last="Maassab">H F Maassab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, Michigan 48109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, Michigan 48109</wicri:regionArea><wicri:noRegion>Michigan 48109</wicri:noRegion></affiliation></author><author><name sortKey="Bryant, M L" sort="Bryant, M L" uniqKey="Bryant M" first="M L" last="Bryant">M L Bryant</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1999 Oct-Dec</MedlineDate></PubDate></date><idno type="RBID">pubmed:10578119</idno><idno type="pmid">10578119</idno><idno type="doi">10.1002/(sici)1099-1654(199910/12)9:4<237::aid-rmv252>3.0.co;2-g</idno><idno type="wicri:Area/PubMed/Corpus">000373</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000373</idno><idno type="wicri:Area/PubMed/Curation">000373</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000373</idno><idno type="wicri:Area/PubMed/Checkpoint">000612</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000612</idno><idno type="wicri:Area/Ncbi/Merge">000011</idno><idno type="wicri:Area/Ncbi/Curation">000011</idno><idno type="wicri:Area/Ncbi/Checkpoint">000011</idno><idno type="wicri:doubleKey">1052-9276::Maassab H:the:development:of</idno><idno type="wicri:Area/Main/Merge">003023</idno><idno type="wicri:Area/Main/Curation">002E48</idno><idno type="wicri:Area/Main/Exploration">002E48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The development of live attenuated cold-adapted influenza virus vaccine for humans.</title><author><name sortKey="Maassab, H F" sort="Maassab, H F" uniqKey="Maassab H" first="H F" last="Maassab">H F Maassab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, Michigan 48109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, Michigan 48109</wicri:regionArea><wicri:noRegion>Michigan 48109</wicri:noRegion></affiliation></author><author><name sortKey="Bryant, M L" sort="Bryant, M L" uniqKey="Bryant M" first="M L" last="Bryant">M L Bryant</name></author></analytic><series><title level="j">Reviews in medical virology</title><idno type="ISSN">1052-9276</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Physiological</term><term>Cold Temperature</term><term>Humans</term><term>Influenza A virus (genetics)</term><term>Influenza A virus (growth & development)</term><term>Influenza A virus (immunology)</term><term>Influenza B virus (genetics)</term><term>Influenza B virus (growth & development)</term><term>Influenza B virus (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Vaccines, Attenuated (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adaptation physiologique</term><term>Basse température</term><term>Grippe humaine ()</term><term>Humains</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins atténués (immunologie)</term><term>Virus de la grippe A (croissance et développement)</term><term>Virus de la grippe A (génétique)</term><term>Virus de la grippe A (immunologie)</term><term>Virus influenza B (croissance et développement)</term><term>Virus influenza B (génétique)</term><term>Virus influenza B (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adaptation, Physiological</term><term>Cold Temperature</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adaptation physiologique</term><term>Basse température</term><term>Grippe humaine</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A procedure to attenuate live influenza virus of type A and type B was developed using adaptation of the virus to grow at 25 degrees C (cold adaptation; ca). Through a series of stepwise passages, two stable mutants were obtained and designated as 'Master' strains, one for type A influenza virus (A/Ann Arbor/6/60-H2N2) and one for type B influenza virus (B/Ann Arbor/1/66). These mutants were used in genetic reassortment using either the classical method or more recently described reverse genetics to update the relevant surface antigens of the circulating strains of influenza virus. The derivation is based on the concept of 6/2 where 6 signifies the six internal genes of the master strain and 2 refers to the two genes coding for the two surface glycoproteins HA and NA of the circulating influenza virus. The advantages of this vaccine were demonstrated to be (1) proper level of attenuation, (2) non-transmissibility, (3) genetic stability, (4) presence of the ca and ts markers and (5) immunogenicity involving both local and the cell-mediated immune responses. The clinical trials in infants, children, adults and elderly have provided the necessary data for eventual licensing of this vaccine. The ease of administration (intranasal) safety and high efficacy make this vaccine suitable to prevent influenza virus infection in all age groups.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Bryant, M L" sort="Bryant, M L" uniqKey="Bryant M" first="M L" last="Bryant">M L Bryant</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Maassab, H F" sort="Maassab, H F" uniqKey="Maassab H" first="H F" last="Maassab">H F Maassab</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:10578119
|texte= The development of live attenuated cold-adapted influenza virus vaccine for humans.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:10578119" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |